Source: BioPortfolio

REMICADE: Remicade biosimilars shown to be unsuitable for some

Antibodypositive patients who are being treated with the rheumatoid arthritis treatment Remicade infliximab

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more